Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects

Vaccine

Volumn 26, Issue 1, 2007, Pages 47-58

  Facciabene, Andrea ^a   Aurisicchio, Luigi ^a   Elia, Leonardo ^a   Palombo, Fabio ^a   Mennuni, Carmela ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a  

^a IRBM   (Italy)

Author keywords

Adenovirus; CEA vaccine; Plasmid DNA electroporation

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN HEAT LABILE ENTEROTOXIN A VACCINE; CARCINOEMBRYONIC ANTIGEN HEAT LABILE ENTEROTOXIN B VACCINE; ENTEROTOXIN; PLASMID DNA; TUMOR VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CHAIN; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL POPULATION; FEMALE; GENETIC IMMUNIZATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; GENETIC VECTORS; IMMUNIZATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY; VACCINES, SYNTHETIC;

EID: 36749040951     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.060     Document Type: Article

References (40)

1. Huang E.H., and Kaufman H.L. CEA-based vaccines. Expert Rev Vaccines 1 1 (2002) 49-63
2. Gurunathan S., Wu C.Y., Freidag B.L., and Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12 4 (2000) 442-447
3. Cappelletti M., Zampaglione I., Rizzuto G., Ciliberto G., La Monica N., and Fattori E. Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. J Gene Med 5 4 (2003) 324-332
4. Zucchelli S., Capone S., Fattori E., Folgori A., Di Marco A., Casimiro D., et al. Enhancing B and T cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 74 24 (2000) 11598-11607
5. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 9 (2000) 4635-4640
6. Scheerlinck J.P., Karlis J., Tjelle T.E., Presidente P.J., Mathiesen I., and Newton S.E. In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22 13-14 (2004) 1820-1825
7. Babiuk S., Baca-Estrada M.E., Foldvari M., Storms M., Rabussay D., Widera G., et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20 27-28 (2002) 3399-3408
8. Bronte V. Genetic vaccination for the active immunotherapy of cancer. Curr Gene Ther 1 1 (2001) 53-100
9. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
10. Mennuni C., Calvaruso F., Facciabene A., Aurisicchio L., Storto M., Scarselli E., et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage-optimized cDNA. Int J Cancer 117 3 (2005) 444-455
11. Stevenson F.K., Rice J., Ottensmeier C.H., Thirdborough S.M., and Zhu D. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 199 (2004) 156-180
12. Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G., et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 17 1 (2006) 81-92
13. Rappuoli R., Pizza M., Douce G., and Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 11 (1999) 493-500
14. Williams N.A., Hirst T.R., and Nashar T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol Today 20 2 (1999) 95-101
15. Salmond R.J., Luross J.A., and Williams N.A. Immune modulation by the cholera-like enterotoxins. Expert Rev Mol Med (2002) 1-16
16. de Haan L., Verweij W.R., Feil I.K., Holtrop M., Hol W.G., Agsteribbe E., et al. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology 94 3 (1998) 424-430
17. Nashar T.O., Webb H.M., Eaglestone S., Williams N.A., and Hirst T.R. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci USA 93 1 (1996) 226-230
18. Williams N.A., Stasiuk L.M., Nashar T.O., Richards C.M., Lang A.K., Day M.J., et al. Prevention of autoimmune disease due to lymphocyte modulation by the B-subunit of Escherichia coli heat-labile enterotoxin. Proc Natl Acad Sci USA 94 10 (1997) 5290-5295
19. Gagliardi M.C., Sallusto F., Marinaro M., Langenkamp A., Lanzavecchia A., and De Magistris M.T. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 30 8 (2000) 2394-2403
20. Petrovska L., Lopes L., Simmons C.P., Pizza M., Dougan G., and Chain B.M. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21 13-14 (2003) 1445-1454
21. Pitcovski J., Bazak Z., Wasserman E., Elias O., Levy A., Peretz T., et al. Heat-labile enterotoxin of E. coli: a potential adjuvant for transcutaneous cancer immunotherapy. Vaccine 24 5 (2006) 636-643
22. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., and Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6 12 (2000) 1403-1406
23. Güereña-Burgueño F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 70 4 (2002) 1874-1880
24. Yamanaka H., Ishibashi D., Yamaguchi N., Yoshikawa D., Nakamura R., Okimura N., et al. Enhanced mucosal immunogenicity of prion protein following fusion with B subunit of Escherichia coli heat-labile enterotoxin. Vaccine 24 15 (2006) 2815-2823
25. Richards C.M., Aman A.T., Hirst T.R., Hill T.J., and Williams N.A. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant. J Virol 75 4 (2001) 1664-1671
26. Verweij W.R., de Haan L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16 20 (1998) 2069-2076
27. Wang J., Zhao C.A., Wang K., Zheng J., Wang Y.L., and Si L.S. Enhanced immunization after intranasal coadministration of Escherichia coli heat-labile enterotoxin B subunit and human papillomavirus 16-L1 DNA vaccine. Chin Med J (Engl) 119 5 (2006) 408-411
28. Minke W.E., Roach C., Hol W.G., and Verlinde C.L. Structure-based exploration of the ganglioside GM1 binding sites of Escherichia coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Biochemistry 38 18 (1999) 5684-5692
29. Facciabene A., Aurisicchio L., and La Monica N. Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol 78 16 (2004) 8663-8672
30. Clarke P., Mann J., Simpson J.F., Rickard-Dickson K., and Primus F.J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58 7 (1998) 1469-1477
31. Rizzuto G., Cappelletti M., Maione D., Savino R., Lazzaro D., Costa P., et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 96 11 (1999) 6417-6422
32. Aarts W.M., Schlom J., and Hodge J.W. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 62 20 (2002) 5770-5777
33. Montgomery D.L., Shiver J.W., Leander K.R., Perry H.C., Friedman A., Martinez D., et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12 9 (1993) 777-783
34. Fraser S.A., de Haan L., Hearn A.R., Bone H.K., Salmond R.J., Rivett A.J., et al. Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect Immun 71 3 (2003) 1527-1537
35. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182 (2001) 18-32
36. Aman A.T., Fraser S., Merritt E.A., Rodigherio C., Kenny M., Ahn M., et al. A mutant cholera toxin B subunit that binds GM1 ganglioside but lacks immunomodulatory or toxic activity. Proc Natl Acad Sci USA 98 15 (2001) 8536-8541
37. Leifert J.A., Rodriguez-Carreno M.P., Rodriguez F., and Whitton J.L. Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 199 (2004) 40-53
38. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 12 (2005) 3623-3633
39. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 6 (2001) 823-832
40. Arrington J., Braun R.P., Dong L., Fuller D.H., Macklin M.D., Umlauf S.W., et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 76 9 (2002) 4536-4546